Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nkarta Inc NKTX

Healthcare Biotechnology
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product... see more

Recent & Breaking News (NDAQ:NKTX)

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

GlobeNewswire May 11, 2023

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

GlobeNewswire April 17, 2023

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire April 12, 2023

Nkarta Announces Departure of Chief Financial & Business Officer

GlobeNewswire March 30, 2023

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

GlobeNewswire March 16, 2023

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire February 9, 2023

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

GlobeNewswire January 9, 2023

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

GlobeNewswire December 5, 2022

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

GlobeNewswire December 2, 2022

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire November 9, 2022

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

GlobeNewswire November 7, 2022

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire November 2, 2022

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire August 11, 2022

Nkarta Announces Key Senior Leadership Team Appointments

GlobeNewswire July 25, 2022

Nkarta to Participate at Upcoming Investor Conference

GlobeNewswire May 31, 2022

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

GlobeNewswire May 16, 2022

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire May 12, 2022

Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

GlobeNewswire April 28, 2022

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire April 25, 2022

Nkarta Announces Proposed Public Offering of Common Stock

GlobeNewswire April 25, 2022